Clinical trial
Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic…
NCT00006090 · M.D. Anderson Cancer Center, Other · Withdrawn
Key facts
| NCT number | NCT00006090 |
|---|---|
| Title | Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia |
| Official title | Phase II Study of Arsenic Trioxide (NSC #706363) Therapy for Fludarabine Refractory or Relapsed Chronic Lymphocytic Leukemia |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | arsenic trioxide |
| Enrollment | 0 |
| Start date | Jun 1, 2000 |
| Primary completion | Oct 1, 2001 |
| Completion | Oct 1, 2001 |
| First posted | Mar 25, 2004 |
| Last update posted | Oct 10, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: